Literature DB >> 23010097

Adult-onset Still's disease: clinical, serological and therapeutic considerations.

Chrisoula Iliou1, Charalampos Papagoras, Niki Tsifetaki, Paraskevi V Voulgari, Alexandros A Drosos.   

Abstract

OBJECTIVES: This paper aims to describe the clinical manifestations, laboratory abnormalities and treatment of adult-onset Still's disease (AOSD) in Greek patients.
METHODS: This is a retrospective observational study. Forty-four patients, diagnosed with AOSD, followed since 1985 up to June 2011, were included. The disease course and treatment were recorded and compared to previously published studies.
RESULTS: Twenty-one males and 23 females were identified. Mean age at diagnosis was 38.3 years. The most common clinical manifestations were fever (100%), arthralgias (97.7%), arthritis (93.2%), salmon-coloured rash (84%), myalgias (50%) and sore throat (38.6%). Characteristic laboratory abnormalities were leucocytosis with neutrophilia (81.8%), elevated C-reactive protein (100%) and erythrocyte sedimentation rate (100%). Elevated liver enzymes and hyperferritinaemia were found in 50% and in 59% of the patients respectively. Very high ferritin serum levels (>5000 μg/l) were found in 22.7%. Rheumatoid factor and antinuclear antibodies were negative in all patients. Thirty patients (68.2%) received non-steroidal anti-inflammatory drugs or aspirin with or without corticosteroids. Response to corticosteroids was common (58.9%). When this treatment was ineffective, a disease-modifying anti-rheumatic drug (DMARD), usually methotrexate, was added with a response rate of 63.6%. Anakinra was used in cases resistant to conventional immunosuppressive treatment. Ten out of 44 patients (22.7%) were treated with anakinra and response was achieved in all of them.
CONCLUSIONS: Our results regarding clinical manifestations and laboratory abnormalities were similar to those of previous reports. High ferritin serum levels were reported in all studies of AOSD and are considered as diagnostically valuable. When treatment with corticosteroids and DMARDS had failed, biologic agents such as anakinra were successfully applied.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010097

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  15 in total

Review 1.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 2.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 3.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

Review 4.  Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety.

Authors:  Dongsheng Hong; Zhihai Yang; Shuyin Han; Xingguang Liang; Kuifen Ma; Xingguo Zhang
Journal:  Drug Des Devel Ther       Date:  2014-11-25       Impact factor: 4.162

Review 5.  Interleukin-18 as a diagnostic marker of adult-onset Still's disease in older patients: a case report and review of the literature.

Authors:  Daisuke Usuda; Yoshiki Furumura; Kento Takeshima; Ryusho Sangen; Yasuhiro Kawai; Yuji Kasamaki; Yoshitsugu Iinuma; Tsugiyasu Kanda
Journal:  J Med Case Rep       Date:  2018-07-10

6.  The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies.

Authors:  Piero Ruscitti; Francesco Ursini; Jurgen Sota; Roberto De Giorgio; Luca Cantarini; Roberto Giacomelli
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-06-17       Impact factor: 5.346

Review 7.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

8.  ESR rate can be a marker for coronary artery disease.

Authors:  Tasnim Eghbal Eftekhaari
Journal:  Vasc Health Risk Manag       Date:  2012-12-18

9.  Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.

Authors:  Francisco Ortiz-Sanjuán; Ricardo Blanco; Leyre Riancho-Zarrabeitia; Santos Castañeda; Alejandro Olivé; Anne Riveros; María L Velloso-Feijoo; Javier Narváez; Inmaculada Jiménez-Moleón; Olga Maiz-Alonso; Carmen Ordóñez; José A Bernal; María V Hernández; Walter A Sifuentes-Giraldo; Catalina Gómez-Arango; Eva Galíndez-Agirregoikoa; Juan Blanco-Madrigal; Vera Ortiz-Santamaria; Jordi Del Blanco-Barnusell; Juan R De Dios; Mireia Moreno; Jordi Fiter; Marina de Los Riscos; Patricia Carreira; María J Rodriguez-Valls; M Carmen González-Vela; Vanesa Calvo-Río; Javier Loricera; Natalia Palmou-Fontana; Trinitario Pina; Javier Llorca; Miguel A González-Gay
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

10.  Acute appendicitis complicated with necrotizing fasciitis in a patient with adult-onset Still's disease: A case report.

Authors:  Zheng-Hao Huang; Yu-Chen Chiu; Li-Lu Ho; Hsiu-Lung Fan; Chun-Chi Lu
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.